This text is provided for reference. The official version is published by the Turkish Medicines and Medical Devices Agency (TİTCK).
English translation of the TİTCK guideline (version dated 31.10.2014). The Turkish original is the legally binding text.
Part I – Structures and processes
1.1. Introduction
This Module has been prepared to provide guidance for establishment and maintenance of pharmacovigilance-related quality assurance systems for marketing authorization holders.
The marketing license holders should establish and use proper and effective quality systems to realize the pharmacovigilance activities.
The quality system application should be implemented in accordance with all quality targets in 1.5 and the guiding principles in 1.6 and the importance of ensuring the quality targets for each drug covered by the quality system in fulfilling the pharmacovigilance-related tasks should be considered.
1.2. Pharmacovigilance system
A pharmacovigilance system is defined as a system used by marketing license holders and application holders, the Institution and other organizations to fulfill the legal tasks and responsibilities identified in the Regulation on the Safety of Drugs and designed to monitor the safety of medicinal products and detect any change to their risk-benefit balance.
A pharmacovigilance system is characterized by its structures, processes and outcomes as in other systems. A dedicated Module is included in the Good Pharmacovigilance Process (GVP) for each specific pharmacovigilance process including its necessary structures.
1.3. Quality, quality objectives, quality requirements and quality system
The quality of a pharmacovigilance system can be defined as all the characteristics of the system considered to produce outcomes relevant to the pharmacovigilance objectives according to estimated likelihoods.
In general terms, quality is subject to staging and can be measured. Defining quality requirements beforehand is required to measure if the required degree of quality has been achieved. Quality requirements are those characteristics of a system that are likely to produce the desired outcome, or quality objectives. The overall quality objectives for pharmacovigilance systems are presented under 1.5.
Specific quality objectives and quality requirements directed at the specific structures and processes of the pharmacovigilance systems are provided in each GVP module as appropriate.
The quality system is part of the pharmacovigilance system and has its own structures and processes. It shall cover organizational structure, responsibilities, procedures, processes and resources of the pharmacovigilance system together with appropriate resource management, compliance management and record management.
1.4. Quality cycle
The quality system shall be based on all of the following activities:
- Quality planning: Establishing structures, planning integrated and consistent processes.
- Quality adherence: Carrying out tasks and responsibilities according to quality requirements.
- Quality control and assurance: Monitoring and evaluating how effectively structures and processes have been established and how effectively the processes are being carried out.
- Quality improvements: Correcting and improving the structures and processes where necessary.
1.5. Overall quality objectives for pharmacovigilance
The overall quality objectives of a pharmacovigilance system are as follows:
- Complying with the legal requirements for pharmacovigilance tasks and responsibilities.
- Preventing harm from adverse reactions in humans arising from the use of medicinal products within or outside the terms of marketing authorization or from occupational exposure.
- Promoting the safe and effective use of medicinal products through providing timely information about the safety of medicinal products to patients, healthcare professionals and the public.
- Contributing to the protection of patient and public health.
1.6. Principles for good pharmacovigilance practices
The following principles should guide the design of all structures and processes as well as the conduct of all tasks and responsibilities with the aim of fulfilling the overall quality objectives in Article 1.5:
- The needs of patients, healthcare professionals and the public related to the safety of medicines should be met.
- Upper management should provide leadership in the implementation of the quality system and motivation of all staff members in relation to the quality objectives.
- All persons within the marketing authorization holder should be involved in and support the pharmacovigilance system according to their tasks and assigned responsibilities.
- All persons involved with the organization should engage in continuous quality improvement following the quality cycle in 1.4.
- Resources and tasks should be organised as structures and processes that will support the proactive, risk-proportionate, continuous and integrated conduct of pharmacovigilance.
- All available evidence on the risk-benefit balance of medicinal products should be provided and all relevant aspects that could impact the risk-benefit balance and the use of a product should be considered when making decisions.
- Good cooperation should be devekioed between marketing authorization holders, patients, healthcare professionals, and other relevant institutions and bodies in accordance with the applicable legal provisions.
1.7. Responsibilities of the quality system within the organization
An adequate number of competent, appropriately qualified and trained personnel must be available for the performance of pharmacovigilance activities. The responsibility of the staff should include adherence to the principles defined in 1.6.
In accordance with the quality cycle (see. 1.4.) the staff with management responsibilities in any organization should be responsible for the following:
- Ensuring that the organization documents the quality system as described in 1.12.
- Ensuring that the documents explaining the quality system are subject to document control in relation to their creation, revision, approval and implementation.
- Ensuring that adequate resources are available and that training is provided (see 1.8.).
- Ensuring that suitable and sufficient premises, facilities and equipment are available (see 1.9.).
- Ensuring compliance management (see 1.10.).
- Ensuring appropriate record management (see 1.11.).
- Reviewing the pharmacovigilance system including the quality system at regular intervals with a risk-based approach to verify its effectiveness (see 1.13.) and introducing corrective and preventive measures where necessary.
- Ensuring that mechanisms are present for timely and effective communication.
- Identifying and investigating concerns arising within an organization if non- adherence to the requirements of the quality and pharmacovigilance systems is suspected; taking corrective, preventive and improving action as necessary.
- Ensuring that audits are performed (see 1.13.).
In relation to the management responsibilities described above, the upper management staff should provide leadership by using the items listed below:
- Motivating all staff members based on trust, freedom to speak and acting responsibly and through recognition of staff members’ contributions to the organization.
- Assigning roles, responsibilities and authorities to staff members according to their competencies and communicating and implementing these throughout the organization.
1.8. Training of personnel for pharmacovigilance
Achieving the required quality for the conduct of pharmacovigilance processes and their outcomes by an organization is mainly related to the availability of a sufficient number of competent and appropriately qualified and trained personnel (see 1.7.).
All personnel involved in the performance of pharmacovigilance activities shall receive initial training and continued training. This training shall be relevant to the roles and responsibilities of the personnel [Regulation on The Safety of Medicinal Products Article 5 (5) d and Article 26 (1), (2)].
The organization shall keep training plans and records for documenting, keeping and developing the competences of the personnel [Regulation on The Safety of Medicinal Products Article 26 (3)]. Training plans should be based on the training needs assessment and should be subject to monitoring.
The training should support continuous improvement of relevant skills, the application of scientific progress and professional development, and ensure that staff members have the appropriate qualifications, understanding of relevant pharmacovigilance requirements as well as experience for the assigned tasks and responsibilities. All staff members of the organization should receive information about what to do if they become aware of a safety concern.
There should be a process to check that training is successful and that the training provided results in the appropriate conduct of the tasks and responsibilities related to pharmacovigilance.
Adequate training should also be provided by the organization for those staff members to whom no specific pharmacovigilance tasks and responsibilities have been assigned but who may have an impact on the pharmacovigilance system or the conduct of pharmacovigilance. Such activities include but are not limited to those related to clinical trials, technical product complaints, medical information, sales and marketing, regulatory affairs, legal affairs and audits. Appropriate instructions on the processes to be used in case of urgency, including business continuity (see 1.12.2.) should be provided by the organization to the personnel.
1.9. Facilities and equipment for pharmacovigilance
Achieving the required quality for the conduct of pharmacovigilance processes and their outcomes is also linked with appropriate facilities and equipment used to support the processes. Facilities and equipment should include office space, information technology (IT) systems and (electronic) storage space. These should be located, designed, constructed, adapted and protected to suit their intended purpose (see 1.5.) in line with the quality objectives for pharmacovigilance. Facilities and equipment that are critical for the conduct of pharmacovigilance (see 1.12.2.) should be subject to appropriate checks, adequacy test and/or validation activities to prove their suitability for the intended purpose. There should be processes in place to keep awareness of using valid terminologies in their current versions and to keep the IT systems up-to-date accordingly.
1.10. Compliance management by marketing authorization holders
For the purpose of compliance management, marketing authorization holders must have specific quality system procedures and processes in place in order to ensure the following:
- The continuous monitoring of pharmacovigilance data, the examination of whether options for risk minimization and prevention and appropriate measures are realized.
- The scientific evaluation of all information on the risks of medicinal products as regards patients’ or public health, in particular as regards adverse reactions arising from use of the product within or outside the terms of its marketing authorization or associated with occupational exposure.
- The submission of accurate and verifiable data on serious adverse reactions to TUFAM within the legally required time-limits.
- The quality, integrity and completeness of the information submitted on the risks of medicinal products, including processes to avoid duplicate submissions and to validate signals.
- Communication by the marketing authorization holder with the Institution including new and changing risks, the pharmacovigilance system main file risk management systems, risk minimization activities, periodic benefit/risk evaluation reports, corrective and preventive actions, and post-licensing safety studies.
- The update of product information by the marketing authorization holder in the light of scientific knowledge.
- Appropriate communication of relevant safety information to healthcare professionals and patients.
1.11. Record management
The organization must record all pharmacovigilance information and ensure that it is handled and stored so as to allow accurate and complete reporting, interpretation, checking and verification of that information.
A record management system should be put in place for all documents used for pharmacovigilance activities. The retrievability as well as traceability of the measures taken to investigate safety concerns, the timelines for those investigations, and the decisions on safety concerns, including their date and the decision-making process will therefore be ensured.
The record management system should support the following:
- The quality management of pharmacovigilance data, including their completeness, accuracy and integrity.
- Timely access to all records.
- Effective internal and external communication.
- The retention of documents relating to the pharmacovigilance systems and the conduct of pharmacovigilance for each medicinal product, in accordance with the applicable retention periods.
In addition, marketing authorization holders shall establish mechanisms enabling the traceability and follow-up of adverse reaction reports.
It should be ensured that the fundamental right to personal data protection is fully and effectively guaranteed in all pharmacovigilance activities in conformity with legal provisions. The purpose of safeguarding public health constitutes an important public interest and one must therefore make sure that during the processing of personal data, identifiable personal data are processed only where necessary and only where the parties involved assess this necessity at every stage of the pharmacovigilance process.
Specific measures should therefore be taken as part of a record management system at each stage in the storage and processing of pharmacovigilance data to ensure data security and confidentiality. This should involve strict limitation of access to documents and to databases to authorized personnel respecting the medical and administrative confidentiality of the data.
There should be appropriate structures and processes in place to ensure that pharmacovigilance data and records are protected from damage during the applicable record retention period.
The record management system should be described in a record management policy.
1.12. Documentation of the quality system
All elements, requirements and provisions adopted for the quality system shall be documented in a systematic and orderly manner in the form of written policies and procedures, such as quality plans, quality manuals and quality records.
A quality plan documents the specified quality objectives and sets out the processes to be implemented to achieve these targets. A procedure is a specified way to carry out a process and may be in the form of a standard operating procedure and other work instruction or quality manual. A quality manual documents the scope of the quality system, the processes of the quality system and the interaction between the two. A quality record is a document stating results achieved or providing evidence of activities performed.
In order to have a systematic approach, the organization should define the following in advance: • Quality objectives specific to th organization in accordance with the overall quality objectives provided under article 1.5 and the quality objectives specific to the structures and processes in accordance with each GVP Module.
- Methods for monitoring the effectiveness of the pharmacovigilance system (see 1.13.). The quality system shall be documented by the following:
- Documents on organizational structures and assignments of tasks to personnel (see. 1.12.1.).
- Training plans and records (see 1.8.).
- Instructions for the compliance management processes (see 1.10.).
- Appropriate instructions on the processes to be used in case of urgency, including business continuity (see 1.12.2.).
- Performance indicators used to continuously monitor the good performance of pharmacovigilance activities.
- Reports of quality audits and follow-up audits, including their dates and results.
Training plans and records must be stored and kept ready for audit and inspection.
It is recommended that the quality system documentation also include the following:
- The methods of monitoring the efficient operation of the quality system and in particular its ability to fulfill the quality objectives.
- The record management policy.
- Records and reports relating to the facilities and equipment including functionality checks, qualification and validation activities which demonstrate that all steps required by the applicable requirements, protocols and procedures have been taken.
- Records to demonstrate that deficiencies and deviations from the established quality system are monitored, that corrective and preventive actions have been taken and that solutions have been applied to the deviations or deficiencies and that the effectiveness of the actions taken has been verified
1.12.1. Additional quality system documentation by marketing authorization holders
In addition to the quality system documentation in accordance with 1.12, marketing authorization holders should document the following:
- Their human resource management in the pharmacovigilance system master file (PSMF).
- Job descriptions defining the duties of the managerial and supervisory staff.
- An organizational chart defining the hierarchical relationships of managerial and supervisory staff.
- Instructions on critical processes in the pharmacovigilance system master file (see 1.12.2.).
- The record management systems in the pharmacovigilance system master file.
The documentation of the quality system additionally includes the organizational structures and assignments of tasks, responsibilities and authorities to all personnel directly involved in pharmacovigilance tasks.
The requirements for the method of documentation of the quality system in the pharmacovigilance system main file or its annexes will be explained in the pharmacovigilance system main file module.
1.12.2. Critical pharmacovigilance processes and business continuity
The pharmacovigilance processes that should be considered as critical include the following:
- Continuous safety profile monitoring and benefit-risk evaluation of medicinal products.
- Establishing, assessing and implementing risk management systems and evaluating the effectiveness of risk minimization.
- Collection, processing, management, quality control, follow-up for missing information, coding, classification, duplicate detection, evaluation and timely electronic transmission to the Institution of individual case safety reports (ICSRs) from any source.
- Signal management.
- Scheduling, preparation (including data evaluation and quality control), submission and assessment of periodic benefit/risk evaluation reports.
- Meeting commitments and responding to requests from the Institution with correct and complete information.
- Interaction between the pharmacovigilance and product quality defect systems.
- Communication about safety concerns between marketing authorization holders and the Institution, in particular notifying changes to the risk-benefit balance of medicinal products.
- Communicating information to patients and healthcare professionals about changes to the risk-benefit balance of medicinal products for the aim of safe and effective use of medicinal products.
- Keeping product information up-to-date with the current scientific knowledge, including the conclusions of the assessment and recommendations from the applicable competent authority.
- Variations to marketing authorizations for safety reasons due to urgency.
Business continuity plans should be established in a risk-based manner and should include the following:
- Provisions for events that could severely impact on the organization’s staff and infrastructure in general or on the structures and processes for pharmacovigilance in particular.
- Back-up systems for urgent exchange of information within an organization, among organizations sharing pharmacovigilance tasks as well as between marketing authorization holders and the Institution.
1.13. Monitoring of the performance and effectiveness of the pharmacovigilance system and its quality system
Processes to monitor the performance and effectiveness of a pharmacovigilance system and its quality system should include:
- Reviews of the systems by those responsible for their management.
- Audits.
- Compliance monitoring.
- Inspections.
- Evaluating the effectiveness of actions taken with medicinal products for the purpose of minimising risks and supporting their safe and effective use in patients.
The organization may use performance indicators to continuously monitor the good performance of pharmacovigilance activities in relation to the quality requirements. The quality requirements for each pharmacovigilance process are provided in each Module of the GVP as appropriate.
The requirements for the quality system itself are provided in this Module. The effectiveness of the system should be monitored by managerial staff and the quality system documentation (see 1.12.) should be evaluated at regular intervals. The frequency and the extent of the reviews are to be determined in a risk-based manner. Pre-defined programs for the review of the system should therefore be present. Reviews of the quality system should include the review of standard operating procedures and work instructions, deviations from the established quality system, audit and inspections reports as well as the use of the indicators referred to above.
Risk-based audits of the quality system must be performed at regular intervals to ensure that it complies with the requirements for the quality system, the human resource management, the compliance management, the record management and the data retention and to ensure its effectiveness. Audits of the quality system should include an audit of the pharmacovigilance system. The methods and processes for the audits will be described in related module. A report should be drawn up on the results for each quality audit and any follow-up audits and sent to the management responsible for the matters audited. The report should include the results of the audit of each aspect of the pharmacovigilance system.
Corrective and preventive measures should be implemented when deemed necessary as a consequence of the monitoring of the performance and effectiveness of a pharmacovigilance system and its quality system (including performing audits). Corrective actions, including a follow-up audit of deficiencies, should be performed when necessary and especially as a result of audits. Additionally, the Institution should have in place arrangements for monitoring the compliance of marketing authorization holders with legal requirements.
1.14. Preparedness planning for pharmacovigilance in public health emergencies
All pharmacovigilance systems should be adaptable to public health emergencies and preparedness plans should be developed as appropriate.
Part II – Overall Responsibilities
2.1. Overall pharmacovigilance responsibilities of the marketing authorization holder
The authorization license holder should use a pharmacovigilance system and create and use an effective quality system that is adequate for implementing pharmacovigilance activities.
It may be necessary for a marketing authorization holder to establish more than one pharmacovigilance system for particular types of products (e.g. vaccines, products available without medical prescription).
A description of the pharmacovigilance system should be developed by the applicant in the format of a pharmacovigilance system master file and be maintained by the marketing authorization holder for all authorized medicinal products. The applicant or the marketing authorization holder is also responsible for developing and maintaining product-specific risk management systems.
Guidance on the structures and processes on how the marketing authorization holder should conduct the pharmacovigilance tasks and responsibilities is provided in different GVP Modules.
2.1.1. Responsibilities of the marketing authorization holder in relation to the qualified person responsible for pharmacovigilance
As part of the pharmacovigilance system, there should be a permanent and continuous appropriately qualified pharmacovigilance officer and pharmacovigilance officer deputy to be responsible for pharmacovigilance in Turkey.
A joint pharmacovigilance officer and deputy can be appointed if separate marketing authorization holders under the same partnership manage a common pharmacovigilance system. However, this person or these persons cannot conduct another task in addition to being the pharmacovigilance officer.
If the marketing authorization holder conducts all the tasks related to pharmacovigilance system through a pharmacovigilance service organization, it may not wish to employ a pharmacovigilance official within its structure. However, if it conducts part of the tasks related to a pharmacovigilance system through a pharmacovigilance service organization, it should employ a pharmacovigilance officer within its structure continuously and permanently. [Regulation on Safety of Medicinal Products Article (5), (6)].
The duties of the pharmacovigilance officer should be defined in a job description. The hierarchical relationship of the pharmacovigilance officer shall be defined in an organizational chart together with those of other managerial and supervisory staff.
Information relating to the pharmacovigilance officer shall be added to the pharmacovigilance system master file.
The marketing authorization holder shall ensure that the pharmacovigilance officer has sufficient authority to influence the quality system and the pharmacovigilance activities.
The marketing authorization holder should ensure that structures and processes are in place so that the pharmacovigilance officer can fulfill the responsibilities listed in 2.1.12. In order to do this, the marketing authorization holder should ensure that mechanisms are in place so that the pharmacovigilance officer can access all information he/she considers relevant, in particular regarding the following:
- Emerging safety concerns and any other information relating to the benefit-risk evaluation of the medicinal products covered by the pharmacovigilance system.
- Ongoing or completed clinical trials and other studies the marketing authorization holder is aware of and which may be relevant to the safety of the medicinal products.
- Information from sources other than from the marketing authorization holder.
- The procedures relevant to pharmacovigilance that are in place at every level in order to ensure consistency and compliance across the organization.
The outcome of the regular reviews of the quality system referred to in 1.7 and 1.13 and the measures used should be communicated by the managerial staff to the pharmacovigilance officer.
Compliance information should be provided to the pharmacovigilance officer on a periodic basis. In particular with regard to its adverse reaction database (or other systems to compare adverse reaction reports), the marketing authorization holder should implement a procedure to ensure that the pharmacovigilance officer is able to obtain information from the database, for example to respond to urgent requests for information from the Institution, at any time. If this procedure requires the involvement of other personnel, for example database specialists, then the marketing authorization holder should make the necessary arrangement for supporting the pharmacovigilance officer outside of normal working hours.
When a marketing authorization holder intends to expand its product portfolio (for example, by acquisition of another company or by purchasing individual products from another marketing authorization holder), the pharmacovigilance officer should be notified as early as possible in order that the potential impact of this procedure on the pharmacovigilance system can be assessed and the system be adapted accordingly. The pharmacovigilance officer may also have a role in determining what pharmacovigilance data should be requested from the other company, either before or after the acquisition. In this situation, he/she should be aware of the contractual arrangements that relate to responsibilities for pharmacovigilance activities and safety data exchange and have the authority to request amendments.
When a marketing authorization holder intends to establish a partnership with another marketing authorization holder, organization or person, the pharmacovigilance officer should be informed early and be involved in the preparation of the contractual arrangements (see 2.1.3.) so that all necessary provisions relevant to the pharmacovigilance system are included.
2.1.1.1 Qualifications of the pharmacovigilance officer
The marketing authorization holder should ensure that the pharmacovigilance officer has adequate theoretical and practical knowledge for the performance of pharmacovigilance activities.
Pharmacovigilance officers who have not completed basic training given by the Institution must apply for the first training program. If the pharmacovigilance officers who are assigned will not participate in the first training conducted by the Institution without a valid excuse, they cannot continue their tasks as pharmacovigilance officer.
2.1.1.2. Role of the pharmacovigilance officer
The pharmacovigilance officer shall be responsible for the establishment and maintenance of the marketing authorization holder’s pharmacovigilance system. He/she should therefore have sufficient authority to influence the performance of the quality system and conductance of the pharmacovigilance activities and to promote, maintain and improve compliance with the legal requirements. Hence, the pharmacovigilance officer should have access to the pharmacovigilance system master file. The pharmacovigilance officer should be in a position of authority regarding the pharmacovigilance system main file to ensure and to verify that the information contained in the pharmacovigilance system under his responsibility is accurate and current.
In relation to the medicinal products covered by the pharmacovigilance system, the specific additional responsibilities of the pharmacovigilance officer include the following:
- Having information on the medicinal product safety profiles and any emerging safety concerns.
- Having information on any conditions or obligations relating to the safety or the safe use of the medicinal products.
- Having information on risk minimization measures.
- Knowing the content of risk management plans and having sufficient relevant authority.
- Being involved in the review of post-authorization safety studies and sign-off of protocols pursuant to a risk management plan.
- Having information on post-authorization safety studies requested by the Institution including the results of studies.
- Ensuring the conduct of pharmacovigilance activities and the submission of all pharmacovigilance-related documents in accordance with the legal requirements and GVP.
- Ensuring the necessary quality including correctness and completeness of pharmacovigilance data in documents submitted to the Institution.
- Ensuring a full and prompt response to any request from the Institution for the provision of additional information necessary for the benefit-risk evaluation of medicinal products.
- Providing any other information relevant to the benefit-risk evaluation to the Institution.
- Providing input into the preparation of regulatory action in response to emerging safety concerns (e.g. variations, urgent safety restrictions, and communication with patients and healthcare professionals).
The responsibility of the pharmacovigilance officer for the pharmacovigilance system means that the he/she has oversight over the functioning of the system in all relevant aspects, including the quality system (e.g. standard operating procedures, contractual arrangements, database operations, compliance data within the context of quality, completeness and timeliness of expedited reporting and submission of periodic update reports, audit reports and training of personnel in relation to pharmacovigilance). Specifically for the adverse reaction database and if applicable, the pharmacovigilance officer should be aware of the validation status of the database, including any failures that occurred during validation and corrective actions. The pharmacovigilance officer should also be informed of significant changes that are made to the database (e.g., changes that could have an impact on pharmacovigilance activities).
2.1.2. Specific quality system processes of the marketing authorization holder
In applying the requirements set out in Article 1.10, the marketing authorization holder shall put in place the following additional specific quality system processes:
- The monitoring with systematic or regular investigations of the use of the MedDRA terminology referenced in Regulation on the Safety of Medicinal Products Article 5 (3) in the classification, presentation, accessibility, risk/benefit determination and evaluation and electronic data exchange and communication
- The retention of minimum elements of the pharmacovigilance system master file as long as the system described in the main file exists and for at least five years after it has been formally terminated by the marketing authorization holder.
- The retention of pharmacovigilance data and documents relating to medicinal products as long as the marketing authorization of the medicinal product exists and for at least further 10 years after the marketing authorization has ceased to exist.
- The marketing authorization holder continuously monitoring published data and keeping the product information up-to-date in the light of scientific data.
During the retention period, retrievability of the documents should be ensured. Documents can be retained in electronic format, provided that the electronic system has been appropriately validated and has appropriate arrangements for system security, access and backup of data. If documents in paper format are transferred into an electronic format, the transfer process should ensure that all of the information present in the original format is retained in a legible manner and that the media used for storage will remain readable over time.
Documents transferred in situations where the business of the marketing authorization holder is taken over by another organization should be complete.
2.1.3. Quality system requirements for pharmacovigilance tasks subcontracted by the marketing authorization holder
The marketing authorization holder may subcontract certain activities of the pharmacovigilance system to third parties to a pharmacovigilance service organization or a service provider. The marketing authorization holder shall nevertheless retain full responsibility for the completeness and accuracy of the pharmacovigilance system master file.
The ultimate responsibility for the fulfillment of all pharmacovigilance tasks and responsibilities and the quality and integrity of the pharmacovigilance system always remains with the marketing authorization holder.
Where a marketing authorization holder has subcontracted some or all of its pharmacovigilance tasks, it shall retain responsibility for ensuring that an effective quality system is applied in relation to those tasks. All guidance provided in the GVP is also applicable for the contracted parties. The contracted parties are also subject to inspection by the Institution.
When subcontracting tasks to a pharmacovigilance service organization, the marketing authorization holder shall draw up subcontracts and keep these detailed and up-to-date. The contractual arrangements between the marketing authorization holder and the other organization, describing the authority and responsibilities of each party should be clearly documented. A description of the subcontracted activities and/or services should be included in the pharmacovigilance system master file and a list of the subcontracts should be included in an annex to the pharmacovigilance master file, specifying the product(s) concerned.
Contractual arrangements should be prepared with the aim of enabling compliance with the legal requirements by each party involved. The marketing authorization holder should include sufficiently detailed descriptions of the delegated tasks, the interactions and data exchange together with timelines. The contract should also contain clear information on the practical management of pharmacovigilance as well as related processes, including those for the maintenance of pharmacovigilance databases. It should also indicate which processes will be in place for checking whether the agreed arrangements are being adhered to on an ongoing basis. In this respect, regular risk-based audits of the other organization by the marketing authorization holder or the use of other methods of control and assessment are recommended.
